Tetra Bio-Pharma has announced new promising preclinical results with ARDS-003 (onternabez) from live SARS-CoV-2 virus infection studies, as well as a septic lung model, carried out by independent researchers.

Shionogi has reported that S-217622 (ensitrelvir fumaric acid), the company's orally administered antiviral drug for COVID-19, shows high in vitro antiviral activity against the SARS-CoV-2 Omicron subvariant BA.2.75.

NanoViricides has outlined plans to develop NV-387-T for monkeypox virus. NV-387-T is made by encapsulating tecovirimat within NV-387 polymeric micelles.

HDT Bio has been awarded a nearly USD 1.8 million grant from the U.S. Army Medical Research Acquisition Activity to develop HDT-201 into an antiviral intranasal spray that can stimulate the body's innate immune system to treat and prevent a broad spectrum of deadly human viruses.

SymBio Pharmaceuticals has entered into a collaboration agreement with the National Institute of Neurological Disorders and Stroke (NINDS) on the evaluation of brincidofovir's potential antiviral effect on Epstein Barr virus (EBV).

Infex Therapeutics has been awarded a grant of GBP 850,000 by Innovate UK Biomedical Catalyst to support its 18-month COV-X project, currently in the preclinical phase, on the optimization of a novel series of SARS-CoV-2 inhibitors.

Shanghai Shengdi Pharmaceutical, Shanghai Senhui Pharmaceutical and Jiangsu Hengrun Pharmaceutical have divulged new cephems (cephalosporins) reported to be useful for the treatment of Gram-negative bacterial infections.

Innovation Pharmaceuticals' brilacidin, a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.

Several hepatitis A outbreaks have occurred in recent years. Although vaccines exist, effective antivirals against hepatitis A virus (HAV) are lacking, and knowledge gaps remain regarding the viral replication cycle.